学术报告（生物技术研究所）

Daniel E. Johnson, Ph.D.

Talk title:

Role of the MEK/ERK Pathway and Src Family Kinases (SFKs) in Myeloid Differentiation

Daniel E. Johnson, Ph.D., Associate Professor, Departments of Medicine and Pharmacology; Division of Hematology/Oncology, University of Pittsburgh, and the University of Pittsburgh Cancer Institute.

Dr. Johnson received his Ph.D. in Molecular Biology from Princeton University in 1988, where he was the first to clone cDNAs encoding the p75 nerve growth factor receptor. He trained as a postdoctoral fellow in Molecular Biology at the University of California at San Francisco from 1988-1992, where he participated in the first cloning of the fibroblast growth factor receptor. Since 1993, Dr. Johnson has been a faculty member at the University of Pittsburgh, and a member of the University of Pittsburgh Cancer Institute.

Dr. Johnson’s research is focused on two main areas. In the first area, he is seeking to understand the molecular mechanisms responsible for regulating myeloid differentiation. These studies are focused on the role of cellular kinases and the development of therapeutic strategies for acute myeloid leukemia. Dr. Johnson’s second area of research involves the development of novel therapeutic approaches in head and neck cancer. These studies are focused on the development and application of small molecules that target Bcl-2 family members and cell survival pathways in head and neck squamous cell carcinoma.

Dr. Johnson currently serves as Section Editor for the journal Leukemia. In addition, he has served on the “Leukemia, Immunology, and Blood Cell Development” study section of the American Cancer Society. He currently serves as a permanent member of the “Drug Discovery and Molecular Pharmacology” study section of the National Institutes of Health. He frequently serves as an abstract reviewer and coordinating reviewer for the American Society of Hematology.

主持：张学光教授

时间：2008年12月12日(周五）下午14：00

地点：苏州大学独墅湖校区炳麟图书馆720会议室